Tempus AI (NASDAQ:TEM) Shares Down 5.2% – Should You Sell?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price fell 5.2% during mid-day trading on Thursday . The company traded as low as $53.48 and last traded at $53.4570. 2,509,433 shares traded hands during trading, a decline of 54% from the average session volume of 5,434,055 shares. The stock had previously closed at $56.41.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus officially launched a blood-based cancer test kit — investors interpreted this as a near-term commercial catalyst and demand driver. Tempus AI (TEM) Unveils Cancer Test Kit, Soars 13.9%
• Positive Sentiment: Commercial collaboration with Predicta Biosciences to expand a co-branded whole-genome sequencing assay (GenoPredicta™) for hematologic malignancies — strengthens Tempus’ assay portfolio and commercial reach in oncology diagnostics. Tempus AI Shares Gain on Commercial Partnership With Predicta Biosciences
• Positive Sentiment: Company had 31 abstracts accepted at the AACR Annual Meeting (including one oral presentation) — boosts scientific validation and visibility for Tempus’ AI and oncology data assets. Tempus Announces 31 Abstracts for Presentation at the AACR Annual Meeting 2026
• Positive Sentiment: Analyst activity: TD Cowen raised coverage to Buy and Jefferies initiated coverage — added fresh institutional interest and helped earlier upside. Tempus AI Raised to “Buy” at TD Cowen Jefferies Initiates Coverage on Tempus AI
• Positive Sentiment: Unusual options activity: large spike in call buying (≈32,900 calls) indicates speculative bullish positioning that likely amplified recent intraday moves.
• Neutral Sentiment: Investor visibility from conferences and product demos (Needham conference presentation, abstracts, and new “Active Follow-Up” workflow) is driving attention but may be more sentiment than immediate revenue. Needham Conference Transcript
• Negative Sentiment: Heavy insider and institutional selling highlighted in recent summaries (multiple insider sales and large fund redemptions/rotations) — increases likelihood of near-term selling pressure. QuiverQuant coverage noting insider selling and activity
• Negative Sentiment: Technical and balance-sheet context: stock remains volatile (beta ~4.9), is below its 200‑day moving average, and has a notable debt-to-equity ratio — factors that can amplify downward moves during profit-taking or market weakness.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TEM. Mizuho began coverage on Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Guggenheim lowered their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Robert W. Baird assumed coverage on Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target on the stock. Finally, Canaccord Genuity Group dropped their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $71.36.

Tempus AI Stock Performance

The business has a fifty day simple moving average of $50.78 and a two-hundred day simple moving average of $66.28. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. The company has a market cap of $9.76 billion, a P/E ratio of -38.71 and a beta of 4.90.

Insider Buying and Selling

In other Tempus AI news, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the transaction, the chief executive officer owned 694,354 shares of the company’s stock, valued at approximately $41,001,603.70. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total value of $10,899,350.00. Following the completion of the transaction, the chief executive officer directly owned 8,941,533 shares in the company, valued at $586,206,903.48. This trade represents a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 563,841 shares of company stock valued at $32,258,311 in the last 90 days. Insiders own 26.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TEM. Royal Bank of Canada grew its position in shares of Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Tempus AI during the first quarter worth about $116,000. Prudential Financial Inc. purchased a new stake in shares of Tempus AI during the second quarter worth about $276,000. Russell Investments Group Ltd. grew its position in shares of Tempus AI by 21.3% during the second quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Tempus AI by 2,926.6% during the second quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after purchasing an additional 204,629 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.